1. Home
  2. KALV vs TKNO Comparison

KALV vs TKNO Comparison

Compare KALV & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • TKNO
  • Stock Information
  • Founded
  • KALV N/A
  • TKNO 1996
  • Country
  • KALV United States
  • TKNO United States
  • Employees
  • KALV N/A
  • TKNO N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • TKNO Medicinal Chemicals and Botanical Products
  • Sector
  • KALV Health Care
  • TKNO Health Care
  • Exchange
  • KALV Nasdaq
  • TKNO Nasdaq
  • Market Cap
  • KALV 418.1M
  • TKNO 390.7M
  • IPO Year
  • KALV N/A
  • TKNO 2021
  • Fundamental
  • Price
  • KALV $8.36
  • TKNO $7.73
  • Analyst Decision
  • KALV Strong Buy
  • TKNO Buy
  • Analyst Count
  • KALV 6
  • TKNO 2
  • Target Price
  • KALV $26.25
  • TKNO $5.00
  • AVG Volume (30 Days)
  • KALV 421.6K
  • TKNO 206.5K
  • Earning Date
  • KALV 12-31-2024
  • TKNO 11-07-2024
  • Dividend Yield
  • KALV N/A
  • TKNO N/A
  • EPS Growth
  • KALV N/A
  • TKNO N/A
  • EPS
  • KALV N/A
  • TKNO N/A
  • Revenue
  • KALV N/A
  • TKNO $36,347,000.00
  • Revenue This Year
  • KALV N/A
  • TKNO $3.47
  • Revenue Next Year
  • KALV N/A
  • TKNO $12.07
  • P/E Ratio
  • KALV N/A
  • TKNO N/A
  • Revenue Growth
  • KALV N/A
  • TKNO N/A
  • 52 Week Low
  • KALV $7.98
  • TKNO $1.16
  • 52 Week High
  • KALV $16.88
  • TKNO $8.91
  • Technical
  • Relative Strength Index (RSI)
  • KALV 36.75
  • TKNO 51.60
  • Support Level
  • KALV $8.48
  • TKNO $7.00
  • Resistance Level
  • KALV $9.30
  • TKNO $8.89
  • Average True Range (ATR)
  • KALV 0.65
  • TKNO 0.74
  • MACD
  • KALV -0.06
  • TKNO -0.09
  • Stochastic Oscillator
  • KALV 17.12
  • TKNO 38.24

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.

Share on Social Networks: